Actuate Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). The Company is developing elraglusib, a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3b, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, which lead to tumor cell survival, growth, migration, and invasion. Its candidate products are Elraglusib Injection and Elraglusib Oral Tablet. Elraglusib is the lead drug in the portfolio and is being evaluated in a randomized Phase II trial in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC). Elraglusib is designed to act as a mediator of antitumor immunity through the inhibition of NF-kB and regulates multiple immune checkpoints and immune cell function.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
28/08/26	US$1.655	-2.07%	231,304
27/08/26	US$1.690	-5.06%	366,078
26/08/26	US$1.780	+12.66%	3,304,333
25/08/26	US$1.580	+28.46%	589,187
24/08/26	US$1.230	-3.15%	179,285

Delayed Quote Nasdaq

More quotes

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.655USD

Average target price

10.01USD

Spread / Average Target

+504.98%

Consensus

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Nasdaq 04:00:00 29/08/2026 HKT			5-day change	1st Jan Change
1.655 ^USD	-2.07%		+30.31%	-72.96%

08-15	Actuate Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
06-30	Actuate Therapeutics, Inc.(NasdaqGM:ACTU) dropped from Russell 2000 Dynamic Index	CI

Market Cap	39.74M 34.25M 32.11M 29.31M 55.22M 3.8B 55.39M 381M 149M 1.92B 149M 146M 6.36B	P/E 2026 *	-	P/E 2027 *	-
Enterprise Value	39.74M 34.25M 32.11M 29.31M 55.22M 3.8B 55.39M 381M 149M 1.92B 149M 146M 6.36B	EV / Sales 2026 *	-	EV / Sales 2027 *	-
Free-Float	84.59%	Yield 2026 *	-	Yield 2027 *	-

08-15	Actuate Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
06-30	Actuate Therapeutics, Inc.(NasdaqGM:ACTU) dropped from Russell 2000 Dynamic Index	CI
06-30	Actuate Therapeutics, Inc.(NasdaqGM:ACTU) dropped from Russell 3000E Index	CI
06-30	Actuate Therapeutics, Inc.(NasdaqGM:ACTU) dropped from Russell Small Cap Completeness Index	CI
06-30	Actuate Therapeutics, Inc.(NasdaqGM:ACTU) dropped from Russell 2500 Index	CI
06-29	Actuate Therapeutics, Inc.(NasdaqGM:ACTU) dropped from Russell 3000 Index	CI
06-29	Actuate Therapeutics, Inc.(NasdaqGM:ACTU) dropped from Russell 2000 Index	CI
06-29	Actuate Therapeutics, Inc.(NasdaqGM:ACTU) dropped from Russell Small Cap Comp Growth Benchmark	CI
06-29	Actuate Therapeutics, Inc.(NasdaqGM:ACTU) dropped from Russell 3000 Growth Benchmark	CI
06-29	Actuate Therapeutics, Inc.(NasdaqGM:ACTU) dropped from Russell 3000E Growth Benchmark	CI
06-29	Actuate Therapeutics, Inc.(NasdaqGM:ACTU) dropped from Russell 2500 Growth Benchmark	CI
06-29	Actuate Therapeutics, Inc.(NasdaqGM:ACTU) dropped from Russell 2000 Growth Benchmark	CI
06-09	Actuate Therapeutics Says Elraglusib to be Evaluated in Phase 1/2 Trial to Find Treatments for Pediatric Neuroblastoma	MT

04-15	B. Riley Cuts Actuate Therapeutics Price Target to $8 From $20, Maintains Buy Rating	MT
26/08/25	B. Riley Initiates Actuate Therapeutics With Buy Rating, $20 Price Target	MT

Actuate Therapeutics, Inc. Stock

Stocks

ACTU

US0050831009

Biotechnology & Medical Research

Valuation : Actuate Therapeutics, Inc.

Chart: Actuate Therapeutics, Inc.

Latest news : Actuate Therapeutics, Inc.

Analysts' recommendations : Actuate Therapeutics, Inc.

Press Releases : Actuate Therapeutics, Inc.

Quotes and Performance

Price Extremes

Managers and Directors : Actuate Therapeutics, Inc.

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Analysts' Consensus

Quarterly revenue - Rate of surprise

06-09	Actuate Therapeutics’ Elraglusib Selected for Evaluation in BEACON2 Trial for High-Risk Pediatric Neuroblastoma	AQ
06-01	Actuate Therapeutics Announces ASCO Poster Presentations Demonstrating Compelling Clinical and Biomarker Data for Elraglusib in First-Line Metastatic Pancreatic Cancer	AQ
05-11	Actuate Therapeutics Announces FDA Clearance of IND for Oral Elraglusib and Strategic Initiatives to Advance the Elraglusib Development Program	AQ
05-06	Actuate Therapeutics Announces Key Appointment of Industry Veteran to Board of Directors	AQ
04-14	Actuate Therapeutics Announces Nature Medicine Publication of Clinical Trial Results Showing Doubling of the Rate of Survival with Elraglusib Plus Chemotherapy in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma	AQ

1 day	-2.07%
1 week	+30.31%
Current month	+49.10%
1 month	+41.45%
3 months	-18.07%
6 months	-55.87%
Current year	-72.96%

1 week	1.2	1.97
1 month	0.9	1.97
Current year	0.9	7.05
1 year	0.9	9.22
3 years	0.9	11.99
5 years	0.9	11.99
10 years	0.9	11.99

Manager	Title	Age	Since
Daniel Schmitt CEO	Chief Executive Officer	64	01/03/2015
Paul Lytle DFI	Director of Finance/CFO	58	01/02/2024
Steven D. Reich CTO	Chief Tech/Sci/R&D Officer	-	-

Director	Title	Age	Since
Daniel Schmitt BRD	Director/Board Member	64	01/04/2015
Aaron Fletcher CHM	Chairman	46	01/04/2015
Daniel Zabrowski BRD	Director/Board Member	66	01/03/2021

Date	Insider	Type	Main position	Quantity	% Market Cap.
14/8/26	Daniel Schmitt	Exercice	Chief Executive Officer	664,633	2.7779%
21/5/26	Roger Sawhney	Free	Director	15,000	0.0633%
21/5/26	Martin Huber	Free	Director	15,000	0.0633%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ACTUATE THERAPEUTICS, INC.	-2.07%	+30.31%	-80.39%	-	39.74M
WUXI APPTEC CO., LTD.	-1.59%	-3.35%	+52.37%	+91.62%	69.54B
ARGENX SE	-2.35%	+1.16%	+44.31%	+88.08%	64.97B
WUXI BIOLOGICS (CAYMAN) INC.	-3.57%	+0.49%	+35.74%	+10.62%	26.51B
INSMED INCORPORATED	-2.35%	-5.75%	-12.90%	+436.87%	25.89B
BIONTECH SE	-8.37%	-12.43%	+2.08%	-18.39%	25.64B
PHARMAESSENTIA CORPORATION	-0.96%	+10.36%	+283.06%	+429.04%	20.22B
GENMAB A/S	-2.04%	+0.28%	+29.11%	-19.77%	19.98B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-3.36%	-4.93%	+2.30%	+549.93%	15.69B
EXELIXIS, INC.	-1.47%	+0.68%	+45.51%	+142.00%	13.49B
Average	-1.86%	+1.30%	+40.12%	+190.00%	28.2B
Weighted average by Cap.	-1.85%	-1.50%	+50.14%	+149.10%

	2026 *	2027 *
Net sales	-	-
Net income	-	-
Net Debt	-	-